Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Most devices implanted during LAAO procedures are oversized—and patients benefit

Oversized devices are becoming more common as time goes on, which suggests operators are growing increasingly comfortable with this treatment choice.

Boston Scientific Acurate neo2 TAVR

Boston Scientific's new TAVR system associated with high success rate, low mortality rate

The new-look device gained CE mark approval in Europe in 2020, but it has not been approved yet in the United States.

Thumbnail

Socioeconomic status and mental health make a big impact on AVR outcomes

Nontraditional risk factors such as dementia, PTSD, bipolar disorder and low socioeconomic status are all important to consider when patients are candidates for aortic valve replacement. 

Anteris Technologies duravr heart valve

Regulatory Roundup: Updates on Medtronic and LivaNova recalls, FDA-cleared AI models, a new heart valve and more

Read our recap of some of the biggest FDA-related stories that impacted cardiology in the last month.

Medtronic launches Evolut FX TAVR system aortic stenosis

Medtronic’s newest self-expanding TAVR system linked to improved performance

Medtronic presented the real-world data at the PCR London Valves 2022 conference. The company's Evolut FX TAVR system gained FDA approval back in August 2021. 

Edwards Lifesciences Corporation has shared new one-year data on the safety and effectiveness of its Evoque transcatheter tricuspid valve replacement (TTVR) system among patients with tricuspid regurgitation (TR)

Edwards shares new one-year data on transcatheter tricuspid valve replacement

The new findings, presented at the PCR London Valves 2022 conference, focused on mortality and heart failure hospitalization rates. 

Example of fractional flow reserve (FFR) calculated using AI and assessment of the plaque in the vessel on a CT scan of the coronaries. This new type of FFR-CT was shown as a work-in-progress by the vendor Elucid. It was shown for the first time at AHA 2022.

PHOTO GALLERY: AHA 2022

A photo essay from the American Heart Association (AHA) 2022 Scientific Sessions Nov. 5-7 in Chicago.

Brian Lindman, MD, MSCI, medical director of the Structural Heart and Valve Center and an associate professor of medicine, Vanderbilt University Medical Center, explains the new American Heart Association (AHA) Target Aortic Stenosis (AS) program. It was announced at the AHA 2022 meeting and is designed to help screen with echo to find more AS patients.

VIDEO: AHA says aortic stenosis is undertreated and underdiagnosed

Brian Lindman, MD, medical director of the Structural Heart and Valve Center, Vanderbilt University Medical Center, explains the new American Heart Association (AHA) Target Aortic Stenosis (AS) program to screen with echo to find more AS patients. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.